Comparison between Low- and Standard-Dose ACTH Tests in Premature Infants at Risk for Chronic Lung Disease

1999 ◽  
Vol 52 (6) ◽  
pp. 274-278 ◽  
Author(s):  
Päivi Nykänen ◽  
Kirsti Heinonen ◽  
Raimo Voutilainen
Keyword(s):  
At Risk ◽  
Lung Disease ◽  
Premature Infants ◽  
Chronic Lung Disease ◽  
Standard Dose

scholarly journals Methylprednisolone, an alternative to dexamethasone in very premature infants at risk of chronic lung disease

2000 ◽  
Vol 26 (10) ◽  
pp. 1496-1500 ◽  
Author(s):  
P. André ◽  
B. Thébaud ◽  
M.H. Odièvre ◽  
H. Razafimahefa ◽  
V. Zupan ◽  
...  
Keyword(s):  
At Risk ◽  
Lung Disease ◽  
Premature Infants ◽  
Chronic Lung Disease ◽  
Very Premature Infants

The Use of Dexamethasone in Premature Infants at Risk for Bronchopulmonary Dysplasia or Who Already Have Developed Chronic Lung Disease: A Cautionary Note

PEDIATRICS ◽  
1991 ◽  
Vol 88 (2) ◽  
pp. 415-416
Author(s):  
GORDON B. AVERY
Keyword(s):  
At Risk ◽  
Lung Disease ◽  
Bronchopulmonary Dysplasia ◽  
Premature Infants ◽  
Chronic Lung Disease ◽  
Lung Compliance ◽  
Cautionary Note ◽  
Rapid Improvement

In Reply.— Beauty, it is said, is in the eye of the beholder. One can read the literature on treatment of early bronchopulmonarly dysplasia (BPD) with dexamethasone and make the case either that the lady is beautiful or that she is ugly. On the beautiful side, most observers have noted a rapid improvement in lung compliance and a higher incidence of acute weaning off the respirator. Some studies have shown shortened time in oxygen and even shorter hospitalization.

scholarly journals COVID-19 Infection in An HIV-Positive Patient

2021 ◽  
Vol 2 (1) ◽  
pp. 13-14
Author(s):  
Hulya Caskurlu ◽  
Yasemin Cag
Keyword(s):  
Immune Deficiency ◽  
At Risk ◽  
Lung Disease ◽  
Chronic Lung Disease ◽  
Age Groups ◽  
Positive Patient ◽  
Hiv Positive ◽  
Hiv Patients ◽  
Access To Treatment ◽  
Continuous Access

The COVID-19 pandemic affects all age groups but follows a more mortal trajectory in patients with preexisting conditions such as immune deficiency, chronic lung disease, diabetes, and cardiovascular problems. Hence, HIV-positive patients with immune deficiency are at risk, therefore, these patients need to have continuous access to treatment during the pandemic. The number of defined COVID-19 positive HIV patients is very limited even though there are approximately 37.9 million HIV-positive patients globally. Therefore, we decided to publish this study reporting an HIV patient treated for COVID-19 in our clinic.

Closure of a secundum atrial septal defect in two infants with chronic lung disease using the Gore HELEX Septal Occluder

2015 ◽  
Vol 26 (1) ◽  
pp. 79-83 ◽  
Author(s):  
Matt E. Zussman ◽  
Grace Freire ◽  
Shawn D. Cupp ◽  
Gary E. Stapleton
Keyword(s):  
Atrial Septal Defect ◽  
Lung Disease ◽  
Premature Infants ◽  
Chronic Lung Disease ◽  
Septal Defect ◽  
Right Atrial ◽  
Secundum Atrial Septal Defect ◽  
Atrial Septal Defect Closure ◽  
Significant Clinical Improvement ◽  
Helex Septal Occluder

AbstractChildren with a secundum atrial septal defect are usually asymptomatic and are referred for elective closure after 3–4 years of age; however, in premature infants with chronic lung disease, bronchopulmonary dysplasia, or pulmonary hypertension, increased pulmonary blood flow secondary to a left-to-right atrial shunt, may exacerbate their condition. Closure of the atrial septal defect in these patients can result in significant clinical improvement. We report the cases of two premature infants with chronic lung disease, who underwent atrial septal defect closure with the Gore HELEX Septal Occluder and discuss the technical aspects of using the device in these patients and their clinical outcomes.

Chronic Lung Disease of Prematurity

PEDIATRICS ◽  
1985 ◽  
Vol 76 (4) ◽  
pp. 652-652
Author(s):  
JAMES B. SCHICK ◽  
BOYD W. GOETZMAN
Keyword(s):  
Lung Disease ◽  
Premature Infants ◽  
Chronic Lung Disease ◽  
Potential Usefulness ◽  
Maximal Response ◽  
Days Of Therapy ◽  
Different Types ◽  
Toxic Drugs

To the Editor.— The paper by Avery et al,1 further demonstrates the potential usefulness of corticosteroids in chronic lung disease of prematurity. However, initial reports in 1974 and 1975 met with criticism for the use of potentially toxic drugs in premature infants.2,3 In 1983 we retrospectively reviewed 23 infants with chronic lung disease of prematurity who received corticosteroids and identified distinct differences between responders and nonresponders which suggested different types of lung disease.4 Our responders all showed a greater than 30% decrease in AaPo2 by day 6 and showed maximal response by ten days of therapy.

Effect on Growth of Two Different Dexamethasone Courses for Preterm Infants at Risk of Chronic Lung Disease

Pharmacology ◽  
1999 ◽  
Vol 59 (5) ◽  
pp. 266-274 ◽  
Author(s):  
Costantino Romagnoli ◽  
Enrico Zecca ◽  
Giovanni Vento ◽  
Luca Maggio ◽  
Patrizia Papacci ◽  
...  
Keyword(s):  
At Risk ◽  
Lung Disease ◽  
Preterm Infants ◽  
Chronic Lung Disease ◽  
Effect On Growth
Sign in / Sign up

Export Citation Format

Share Document